Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Safety Study Assessing the Adverse Events Occurring Within One Day of TEGSEDI Administration in Patients With Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)

NCT04306510 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.

NCT NCT04306510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04306510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Safety Study Assessing the Adverse Events Occurring Within One Day of TEGSEDI Administration in Patients With Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
Lead sponsor
Akcea Therapeutics
Phase
Phase 4
Overall status
Terminated
Start date
January 21, 2021
Completion date
March 20, 2024
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary transthyretin amyloidosis with polyneuropthy